Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27873130 | 0.98 | ESR1 (0.50) | ESR1ESR2CES2CES1BCHE | |
| SCHEMBL39964 | 0.84 | KDM4E (0.52) | PARP1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL28784267 | 0.83 | PARP1 (0.50) | CES2CES1BCHEPARP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4562961 | 0.82 | PARP1 (0.50) | PARP1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL3837773 | 0.82 | JAK2 (0.48) | CES2CES1BCHEPARP1HPGD | |
| SCHEMBL30327642 | 0.81 | ESR1 (0.46) | ESR1ESR2CES2CES1BCHE | |
| SCHEMBL11476967 | 0.81 | ESR1 (0.53) | ESR1ESR2CES2CES1BCHE | |
| SCHEMBL29570483 | 0.81 | ALB (0.61) | ESR1ESR2CES2CES1BCHE | |
| SCHEMBL8804521 | 0.81 | DGAT1 (0.47) | ESR1ESR2CES2CES1PARP1 | |
| SCHEMBL4451884 | 0.81 | ESR1 (0.53) | ESR1ESR2CES2CES1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| CN-105209429-B | SHIP1 conditioning agents and relative method | 阿奎诺克斯药物（加拿大）公司 | 2018-05-29 | — | — | CN | claimed |
| CN-104540825-B | Azaindole quinoline compound | 霍夫曼-拉罗奇有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-105209429-A | Ship1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | claimed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| CN-101535276-A | 2, 4-diaminopyrimidine fused bicyclic derivatives as ALK and c-MET inhibitors | CEPHALON INC (US) | 2009-09-16 | — | — | CN | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| EP-1848713-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-31 | — | — | EP | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-20060116407-A1 | Amide derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | claimed |
| WO-2006053778-A2 | AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-26 | — | — | WO | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | ESR1 3243/4885ESR2 2199/4885CES2 2558/4885 |
| US-20060116407-A1 | Amide derivatives | GLS, SDHA, GLS2 | ESR1 1498/4885ESR2 764/4885CES2 794/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | ESR1 614/4885ESR2 1509/4885CES2 662/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | ESR1 2915/4885ESR2 2118/4885CES2 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.